Urinary bladder neoplasm

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This study tests a drug called erdafitinib, placed directly into the bladder using a special delivery system, for people with non-muscle-invasive or muscle-invasive bladder cancer. The trial has four parts to find the best dose and check safety and effectiveness. About 235 partic…

This phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This study tests an immunotherapy drug called camrelizumab, given directly into the bladder, for people with high-risk non-muscle invasive bladder cancer that did not respond to BCG treatment. The goal is to find a safe dose and see if it can prevent cancer from coming back or ge…

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 partici…

This study tests a robotic-assisted surgery tool to remove bladder lesions. About 30 adults with small bladder tumors will undergo the procedure. The goal is to see if the robot helps remove the tumor in one piece with healthy tissue around it, which may improve diagnosis and red…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…

This study analyzes genetic changes in bladder cancer cells from 5,000 participants. Researchers hope to identify key chromosomal events linked to the disease. No treatment is given; the goal is to gather knowledge that may inform future research.